Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study

被引：2

作者：

Van Cutsem, E. ^{[1
]}

Yoshino, T. ^{[2
]}

Lenz, H-J. ^{[3
]}

Lonardi, S. ^{[4
]}

Falcone, A. ^{[5
]}

Limon, M. L. ^{[6
]}

Saunders, M. P. ^{[7
]}

Sobrero, A. ^{[8
]}

Maiello, E. ^{[9
]}

Park, Y. S. ^{[10
]}

Ferreiro Monteagudo, R. ^{[11
]}

Hong, Y. S. ^{[12
]}

Tomasek, J. ^{[13
]}

Taniguchi, H. ^{[14
]}

Ciardiello, F. ^{[15
]}

Hocke, J. ^{[16
]}

Oum'hamed, Z. ^{[17
]}

Vlassak, S. ^{[18
]}

Studeny, M. ^{[19
]}

Tabernero, J. ^{[20
]}

机构：

[1] Univ Hosp Leuven, Digest Oncol, Campus Gasthuisberg, Leuven, Belgium

[2] Natl Canc Ctr Hosp East, Dept GI Oncol, Kashiwa, Chiba, Japan

[3] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Med Oncol, Los Angeles, CA USA

[4] Ist Oncol Veneto IRCCS, Oncol Med 1, Padua, Italy

[5] Azienda Osped Univ S Chiara, Oncol Med, Pisa, Italy

[6] Hosp Univ Virgen del Rocio, Med Oncol, Seville, Spain

[7] Christie NHS Fdn Trust, Clin Oncol, Manchester, Lancs, England

[8] Osped San Martino Genova, Dept Med Oncol, Genoa, Italy

[9] Osped Casa Sollievo Sofferenza, Oncohematol, San Giovanni Rotondo, Italy

[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Med, Seoul, South Korea

[11] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain

[12] Univ Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South Korea

[13] InVentiv Hlth, Med Commun, London, England

[14] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[15] AOU SUN, Med Oncol, Naples, Italy

[16] Boehringer Ingelheim Pharma GmbH & Co KG, Stat, Tubingen, Germany

[17] Boehringer Ingelheim BV France SAS, Clin Trials, Reims, France

[18] SCS Boehringer Ingelheim Comm V, Med Affairs, Brussels, Belgium

[19] Boehringer Ingelheim GmbH & Co KG, Div Med, Clin Dev Dept, Vienna, Austria

[20] Vall dHebron Univ Hosp, Inst Oncol, Oncol Med, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw435.12

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA20_PR

引用

页数：1

共 50 条

[21] PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
Paz-Ares, L. G.
De Marinis, F.
Dediu, M.
Thomas, M.
Pujol, J.
Bidoli, P.
Molinier, O.
Sahoo, T. P.
Laack, E.
Reck, M.
Corral, J.
Melemed, S. A.
John, W. J.
Chouaki, N.
Zimmerman, A.
Grul, C. M. Visseren
Gridelli, C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[22] CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
Chen, Eric Xueyu
Jonker, Derek J.
Kennecke, Hagen F.
Berry, Scott R.
Couture, Felix
Ahmad, Chaudhary E.
Goffin, John R.
Kavan, Petr
Harb, Mohammed
Colwell, Bruce
Samimi, Setareh
Samson, Benoit
Abbas, Tahir
Aucoin, Nathalie
Aubin, Francine
Koski, Sheryl L.
Wei, Alice Chia-chi
Magoski, Nadine M.
Tu, Dongsheng
O'Callaghan, Christopher J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[23] Randomized phase III ANGEL study of rivoceranib (apatinib) plus best supportive care (BSC) vs placebo plus BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens
Kang, Y-K.
Kang, W. K.
Di Bartolomeo, M.
Chau, I.
Yoon, H. H.
Cascinu, S.
Ryu, M-H.
Kim, J. G.
Lee, K-W.
Oh, S. C.
Takashima, A.
Kryzhanivska, A.
Chao, Y.
Vladimirov, V.
Evesque, L.
Schenker, M.
McGinn, A.
Sankar, N.
Wyrwicz, L.
Boku, N.
ANNALS OF ONCOLOGY, 2019, 30
[24] PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
Paz-Ares, L. G.
De Marinis, F.
Dediu, M.
Thomas, M.
Pujol, J.
Bidoli, P.
Molinier, O.
Sahoo, T. P.
Laack, E.
Reck, M.
Corral, J.
Melem, S. A.
Grul, C. M. Visseren
Gridelli, C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
[25] The CCTG C0.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.
Chen, Eric Xueyu
Jonker, Derek J.
Kennecke, Hagen F.
Koski, Sheryl L.
Wei, Alice Chia-chi
Magoski, Nadine M.
Tu, Dongsheng
O'Callaghan, Christopheri J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[26] A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study
Daniele, Bruno
Di Maio, Massimo
Gallo, Ciro
Gasbarrini, Antonio
Carteni, Giacomo
Di Costanzo, Giovan Giuseppe
Craxi, Antonio
Cabibbo, Giuseppe
Bolondi, Luigi
Granito, Alessandro
Missale, Gabriele
Frassoldati, Antonio
Angelico, Mario
Roselli, Mario
Daniele, Gennaro
Perrone, Francesco
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[27] A prospective, randomized, double-blinded, placebo controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.
Kang, Yoon-Koo
Boku, Narikazu
Kang, Won Ki
Yoon, Harry H.
Cascinu, Stefano
Al-Batran, Salah-Eddin
Houston, Scott
Park, Cheol Hee
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (PTS) with advanced malignant pleural mesothelioma (MPM)
Jassem, Jacek
Ramlau, Rodryg
Santoro, Armando
Schuette, Wolfgang
Chemaissani, Assad
Hong, Shengyan
Blatter, Johannes
Adachi, Susumu
Hanauske, Axel-R
Manegold, Christian
ANNALS OF ONCOLOGY, 2006, 17 : 214 - 214
[29] Efficacy and safety of fruquintinib (F) plus best supportive care (BSC) vs placebo (P) plus BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Kotani, D.
Yoshino, T.
Paulson, A. S.
Masuishi, T.
Hochster, H.
Krauss, J.
Sunakawa, Y.
Takashima, A.
Yamazaki, K.
Kawakami, H.
Nishina, T.
Komatsu, Y.
Esaki, T.
Eng, C.
Dasari, N. A.
Yu, Z.
Chen, L.
Yang, T.
Schelman, W.
Satoh, T.
ANNALS OF ONCOLOGY, 2023, 34 : S1506 - S1507
[30] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND COLORECTAL CANCER (CRC) SYMPTOMS IN METASTATIC CRC: PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) VS. BSC ALONE BY KRAS TUMOR STATUS
Odom, D.
Devercelli, G.
Bennett, L.
Peeters, M.
Wolf, M.
Amado, R.
VALUE IN HEALTH, 2008, 11 (06) : A487 - A487

← 1 2 3 4 5 →